Ramucirumab/Merestinib + Chemotherapy for Biliary Tract Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since previous systemic therapy for advanced or metastatic disease is not allowed, you may need to discuss your current medications with the trial team.
Is the combination of Ramucirumab/Merestinib with chemotherapy safe for humans?
How is the drug combination of Ramucirumab and Merestinib with chemotherapy unique for treating biliary tract cancer?
What data supports the effectiveness of the drug combination Ramucirumab/Merestinib with chemotherapy for biliary tract cancer?
A study evaluated the addition of ramucirumab or merestinib to standard chemotherapy for advanced biliary tract cancer, aiming to assess their effectiveness and safety. Another study found that ramucirumab, which targets a protein involved in blood vessel growth in tumors, was investigated for its potential benefits in advanced biliary tract cancer previously treated with chemotherapy.12367
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic biliary tract cancer who haven't had previous systemic therapy for their condition. They must be relatively healthy and active (with good performance status), have measurable disease, provide tissue samples, have proper organ function and biliary drainage, and use effective contraception if of childbearing potential.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ramucirumab or merestinib or placebo plus cisplatin and gemcitabine for up to 8 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Merestinib
- Ramucirumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University